An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Dec 2019
Price : $35 *
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PRO-MSACTIVE
- Sponsors Roche
- 18 Sep 2019 Planned End Date changed from 15 Sep 2021 to 1 Mar 2021.
- 18 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2018 Planned End Date changed from 15 Feb 2021 to 15 Sep 2021.